| Characteristic |
No. of patients |
Disease-free survival |
Overall survival |
| 5 years (%) |
P-value* |
5 years (%) |
P-value* |
| iNOS expression in cancer cells |
|
|
0.484 |
|
0.258 |
| 0 |
11 |
72.7 |
|
90.9 |
|
| 1 |
95 |
66.3 |
|
64.2 |
|
| 2 |
56 |
58.9 |
|
64.3 |
|
| iNOS expression in macrophages |
|
|
0.869 |
|
0.384 |
| 0 |
26 |
61.5 |
|
53.8 |
|
| 1 |
54 |
61.1 |
|
63 |
|
| 2 |
56 |
67.9 |
|
73.2 |
|
| 3 |
26 |
65.4 |
|
69.2 |
|
| iNOS expression in cancer cells and macrophages# |
|
|
0.003 |
|
0.01 |
| Group 1 |
59 |
55.9 |
|
54.2 |
|
| Group 2 |
47 |
80.9 |
|
83 |
|
| Group 3 |
21 |
76.2 |
|
76.2 |
|
| Group 4 |
35 |
48.6 |
|
57.1 |
|
| T status |
|
|
0.001 |
|
0.066 |
| pT1 |
8 |
87.5 |
|
87.5 |
|
| pT2 |
25 |
96 |
|
84 |
|
| pT3 |
121 |
59.9 |
|
62 |
|
| pT4 |
8 |
37.5 |
|
50 |
|
| N status |
|
|
< 0.001 |
|
< 0.001 |
| pN0 |
85 |
80 |
|
78.8 |
|
| pN1 |
47 |
63.8 |
|
70.2 |
|
| pN2 |
30 |
20 |
|
23.3 |
|
| Distant metastasis |
|
|
< 0.001 |
|
< 0.001 |
| None detected |
145 |
71 |
|
71 |
|
| Present |
17 |
5.9 |
|
23.5 |
|
| Modified Astler-Coller stage |
|
|
< 0.001 |
|
< 0.001 |
| A |
6 |
100 |
|
100 |
|
| B |
76 |
81.6 |
|
78.9 |
|
| C |
63 |
55.6 |
|
58.7 |
|
| D |
17 |
5.9 |
|
23.5 |
|
| Sex |
|
|
0.67 |
|
0.535 |
| Male |
87 |
62.1 |
|
67.8 |
|
| Female |
75 |
66.7 |
|
64 |
|
| Differentiation |
|
|
0.016 |
|
0.005 |
| Well |
23 |
69.6 |
|
73.9 |
|
| Moderate |
124 |
66.1 |
|
67.7 |
|
| Poor |
15 |
40 |
|
40 |
|
|
| *Log-rank test. # Group 1 (low in cancer cells and macrophages), group 2 (low in
cancer cells and high in macrophages), group 3 (high in cancer cells and low in
macrophages), group 4 (high in cancer cells and macrophages). |
| Table 1: Disease-free and overall survival in 162 colorectal cancer patients. |